Axogen, Inc. Files 8-K on Financials

TL;DR

AXGN dropped an 8-K on Jan 10th covering financials. Check it.

AI Summary

Axogen, Inc. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing also included disclosures under Regulation FD and financial statements. The company, incorporated in Minnesota, is headquartered in Alachua, Florida.

Why It Matters

This filing provides investors with crucial updates on Axogen's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or immediate risks.

Key Players & Entities

• Axogen, Inc. (company) — Registrant
• January 10, 2025 (date) — Date of earliest event reported
• Minnesota (jurisdiction) — State of incorporation
• Alachua, Florida (location) — Address of principal executive offices
• 001-36046 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market

Filing Documents

• axgn-20250110.htm (8-K) — 27KB
• axogenincpressreleasedat.htm (EX-99.1) — 9KB
• axogenincpressreleasedat001.jpg (GRAPHIC) — 229KB
• axogenincpressreleasedat002.jpg (GRAPHIC) — 333KB
• axogenincpressreleasedat003.jpg (GRAPHIC) — 80KB
• 0000805928-25-000006.txt ( ) — 1046KB
• axgn-20250110.xsd (EX-101.SCH) — 2KB
• axgn-20250110_lab.xml (EX-101.LAB) — 21KB
• axgn-20250110_pre.xml (EX-101.PRE) — 12KB
• axgn-20250110_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 10, 2025, Axogen, Inc. (the "Company") issued a press release announcing its preliminary, unaudited fourth quarter and full year 2024 financial performance. A copy of the press release is furnished as Exhibit 99.1. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information in this Item 7.01, including Exhibit 99.1 , is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits See the Exhibit index below, which is incorporated herein by reference. Exhibit No. Description 99.1 Axogen Inc. Press Release dated January 10, 2025, regarding Preliminary 2024 Financial Results 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: January 10, 2025 By: /s/ Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR